Parkinson’s drug from Biogen, Denali comes up short
BioPharma Dive
High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson s patients.
pharminent
May 22, 2026 (Last updated: May 22, 2026)
BioPharma Dive
High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson s patients.
